Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL

https://doi.org/10.17749/2070-4909.2016.9.3.030-037

Full Text:

Abstract

Study objective: pharmacoeconomic evaluation of cephalosporins, protected penicillins and macrolides, most commonly used in the treatment of acute obstructive bronchitis.

Materials and methods. data file of hospitalized patients with acute obstructive bronchitis treatedby antibiotic. The study included 2259 patient’s data files. The age of patients ranged from 0 to 18 years old. «Cost-effectiveness» analysis was used for comparing of the costs and effectiveness for courses of antibiotics, used in therapy of acute obstructive bronchitis.

Results. It is shown that a pharmacoeconomic standpoint, Ceftriaxone (Sintez) was the most effective antibiotic of the cephalosporin group in the treatment of acute obstructive bronchitis in children. The original drug Augmentin (Smithkline Beecham Pharmaceuticals) and generic Amoxiclav (Lek d.d) were used from the group of protected penicillins (combination amoxicillin / clavulanic acid). The effectiveness of Augmentin (0.591) and Amoxiclav (0.530) was comparable. The Augmentin’s course of therapy characterized by a lower value CER in comparison with Amoxiklav. From the pharmacoeconomic point of view treatment course of Azithromycin (Vertex) was the most appropriate of the macrolide antibiotic in the therapy of acute obstructive bronchitis,. The highest value ICER ratio was obtained for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical efficacy. Besides Sumamed is original azithromycin. Azitromicin generics Azitral and Hemomitsin had the lowest ICER after Azithromycin (1151.67 rubles and 1812.22 rubles, respectively).

About the Authors

O. V. Zhukova
FSBI HPE «NizhSMA» MOH Russia
Russian Federation

PhD, senior lecturer of the Department of Management and Economics of Pharmacy and Pharmaceutical Technology of Pharmacy Faculty FSBI HPE «NizhSMA» MOH Russia. Address: pl. Minina i Pozharskogo, 10/1, Nizhnii Novgorod, Russia, 603950. Tel.: +7(831)4650927



S. V. Kononova
FSBI HPE «NizhSMA» MOH Russia
Russian Federation

PhD, professor of the Department of Management and Economics of Pharmacy and Pharmaceutical Technology of Pharmacy Faculty FSBI HPE «NizhSMA» MOH Russia. Address: pl. Minina i Pozharskogo, 10/1, Nizhnii Novgorod, Russia, 603950. Tel.: +7(831)4650927



References

1. Antibacterial therapy. A Practical Guide. Ed. LS Stratchounski, YB Belousov [Antibakterial’naya terapiya. Prakticheskoe rukovodstvo. Pod red. L. S. Strachunskogo, Yu.B. Belousova (in Russian)]. Moscow. 2000.

2. Mizernitskii Yu. L. Pul’monologiya detskogo vozrasta: problemy i resheniya. 2006; 6: 60-5.

3. Samsygina G. A. Pediatriya. 2008; 2: 25-32.

4. Strachunskii L. S., Kozlov S. N. Modern Antimicrobial Chemotherapy. Guidelines for doctors [Sovremennaya antimikrobnaya khimioterapiya. Rukovodstvo dlya vrachei (in Russian)]. Moscow. 2002.

5. Pharmacotherapy in pediatric pulmonology. Ed. SY Kaganova Guide pharmacotherapy in pediatrics and pediatric surgery. Under the total. Ed. HELL. Tsaregorodtseva, AA Tabolina. T. 1 [Farmakoterapiya v pediatricheskoi pul’monologii. Pod red. S. Yu. Kaganova Rukovodstvo po farmakoterapii v pediatrii i detskoi khirurgii. Pod obshch. red. A. D. Tsaregorodtseva, A. A. Tabolina. T. 1 (in Russian)]. Moscow. 2002.

6. Auvichayapat N., Auvichayapat P., Watanatorn J., Thamaroj J., Jitpimolmard S. Kluver-Bucy syndrome after mycoplasmal bronchitis. Epilep Behav. 2006; 8 (1): 320-2.


For citation:


Zhukova O.V., Kononova S.V. METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(3):30-37. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.3.030-037

Views: 225


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)